Reduction in Total (First and Recurrent) Cardiovascular Events with Ezetimibe/Simvastatin compared with Simvastatin Alone post ACS in the IMPROVE-IT Trial Sabina A. Murphy, Christopher Cannon, Robert Giugliano, Michael Blazing, Thomas Musliner, Andrew Tershakovec, Jennifer White, Kelly Im, Naveen Deenadayalu, Haral Darius, Witold Ruzyllo, Andrew Tonkin, Uma Kher, Robert Califf, Eugene Braunwald On behalf of the IMPROVE IT Investigators Background: First vs Total Events ➢ Analysis of long-term ACS trials often use survival analysis methods that take into account the first event a patient experiences during trial – Cox proportional hazards model ➢ However, subjects with a non-fatal event continue to be followed during the trial and can experience additional events – All events, not just first, important to patients and clinicians Background: Cholesterol Lowering ➢ Lowering LDL cholesterol (LDL-C) has been a mainstay of primary and secondary CV prevention ➢ Evidence from trials show reduction with high- intensity statins in total as well as first events post ACS ➢ IMPROVE-IT trial evaluated whether ezetimibe added to simvastatin would provide a clinical benefit compared with simvastatin therapy alone Murphy SA, et al. JACC 2009;54:2358–62 Tikkanen, MJ et al. JACC 2009;54:2353–7 Study Design Patients stabilized post ACS ≤ 10 days: LDL-C 50–125*mg/dL (or 50–100**mg/dL if prior lipid-lowering Rx) N=18,144 Standard Medical & Interventional Therapy Simvastatin 40 mg Ezetimibe / Simvastatin 10 / 40 mg Duration: Minimum 2 ½-year follow-up (5314 events) Primary Endpoint: CV death, MI, hospital admission for UA, coronary revascularization (≥ 30 days after randomization), or stroke Cannon CP AHJ 2008;156:826-32; Califf RM NEJM 2009;361:712-7; Blazing MA AHJ 2014;168:205-12 Primary and 3 Prespecified Secondary Endpoints — First Events Simva* EZ/Simva* p-value 0.936 Primary CVD/MI/UA/Cor Revasc/CVA 0.948 Secondary #1 All D/MI/UA/Cor Revasc/CVA 0.912 Secondary #2 CHD/MI/Urgent Cor Revasc 0.945 Secondary #3 CVD/MI/UA/All Revasc/CVA 0.8 1.0 Ezetimibe/Simva Better 1.1 Simva Better 34.7 32.7 0.016 40.3 38.7 0.034 18.9 17.5 0.016 36.2 34.5 0.035 *7-year event rates (%) UA, documented unstable angina requiring rehospitalization; Cor Revasc, coronary revascularization (≥30 days after randomization); All D, all-cause death; CHD, coronary heart disease death; All Revasc, coronary and non-coronary revascularization (≥30 days) Cannon CP et al, AHA 2014 Hypothesis ➢ We hypothesized that combination ezetimibe/simvastatin would also reduce total events (first + recurrent), compared with simvastatin alone during the median 6-year follow-up after an acute coronary syndrome in IMPROVE-IT Methods Negative Binomial Model - Primary ➢ Modified Poisson model ➢ Counts of total events – Included exposure time in model Wei, Lin and Weissfeld Model - Sensitivity ➢ Extension of survival models based on the Cox proportional hazards – First 4 events included Number of Primary Endpoint Events First Event Revasc Additional Events Total N=9545 Revasc Total Primary Endpoint Events Total N=9545 Total Primary Endpoint Events 4983 # Events Total Events RR 0.91 P=0.007 Simvastatin Alone 4562 -421 Additional Events RR 0.88 (0.79-0.98) -251 1st Event HR 0.936 P=0.016 -170 Ezetimibe Simvastatin Secondary EP: CHD death, MI, urgent revascularization Events 2670 Total Events RR 0.85 P=0.002 2303 # Events Additional Events RR 0.79 (0.69-0.91) -241 1st Event HR 0.912 P=0.016 Simvastatin Alone -367 -126 Ezetimibe Simvastatin Primary and 3 Prespecified Secondary Endpoints — Total Events p-value 0.91 Primary CVD/MI/UA/Cor Revasc/CVA 0.007 0.92 Secondary #1 All D/MI/UA/Cor Revasc/CVA 0.009 0.85 Secondary #2 CHD/MI/Urgent Cor Revasc 0.002 Secondary #3 CVD/MI/UA/All Revasc/CVA 0.93 0.02 Exploratory CVD/MI/CVA 0.88 0.7 Ezetimibe/Simva Better 0.002 1.0 Simva Better 1.2 Total PEP Events by Type of Event 4983 4562 # Events Total NF MI RR 0.87 p=0.004 Total NF Stroke RR 0.77 p=0.005 Simvastatin Alone Ezetimibe Simvastatin Sensitivity Analysis: Wei, Lin, Weissfeld Model for Primary Endpoint Model HR 0.93, 95% CI 0.89, 0.99, p=0.01 First Event (n=5,314) Second Event (n=2,297) Third Event (n=972) Fourth Event (n=456) Model Average HR 0.6 Ezetimibe/Simva Better 1.0 Simva Better 1.3 Total Primary Endpoint Events Events/1000 Patients/Year Risk Differences for 1000 Patients per Year with Ezetimibe/Simva * * * 0 -5 0 -4 -11 * p<0.05; others NS Conclusions ➢ Lipid lowering therapy with ezetimibe/simvastatin improved clinical efficacy with reductions in total primary endpoint events compared with simvastatin alone, driven by reductions in MI, stroke, and urgent revasc ➢ Taking into account total events more than doubled the number of events prevented with ezetimibe/simvastatin combination Conclusions ➢ These data provide further support of the benefit of continuation of intensive combination lipid lowering therapy after a recurrent CV event ➢ Analyses of recurrent events are important as total events have implications: – Patient morbidity – Need for recurrent hospitalizations – Costs ➢ These considerations not always accounted for when analyzing first events only